.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Merck
McKesson
Mallinckrodt
Express Scripts
Accenture
Dow
US Army
Colorcon
Boehringer Ingelheim

Generated: June 29, 2017

DrugPatentWatch Database Preview

PROZAC Drug Profile

« Back to Dashboard

What is the patent landscape for Prozac, and what generic Prozac alternatives are available?

Prozac is a drug marketed by Lilly and Eli Lilly And Co and is included in four NDAs. There are four patents protecting this drug.

This drug has twenty-six patent family members in twenty-three countries.

The generic ingredient in PROZAC is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.

Summary for Tradename: PROZAC

Patents:1
Applicants:2
NDAs:4
Suppliers / Packagers: see list2
Bulk Api Vendors: see list83
Clinical Trials: see list51
Patent Applications: see list3,088
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROZAC at DailyMed

Pharmacology for Tradename: PROZAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
PROZAC
fluoxetine hydrochloride
SOLUTION;ORAL020101-001Apr 24, 1991DISCNYesNo► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-003Jun 15, 1999ABRXYesYes► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987AB1RXYesNo6,960,577► Subscribe ► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-004Jun 15, 1999DISCNNoNo► Subscribe► Subscribe
Lilly
PROZAC WEEKLY
fluoxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021235-001Feb 26, 2001ABRXYesYes5,985,322*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROZAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 19874,035,511► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 19874,083,982► Subscribe
Lilly
PROZAC
fluoxetine hydrochloride
SOLUTION;ORAL020101-001Apr 24, 19914,626,549*PED► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-004Jun 15, 19994,314,081*PED► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-006Dec 23, 19924,194,009► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PROZAC

Country Document Number Estimated Expiration
Australia761510► Subscribe
World Intellectual Property Organization (WIPO)9961027► Subscribe
Canada2332814► Subscribe
Slovakia17512000► Subscribe
Australia4008699► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Novartis
Covington
Boehringer Ingelheim
Queensland Health
Teva
Deloitte
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot